IMMURON LTD-SPON ADR (IMRN) Stock Price, Forecast & Analysis
USA - NASDAQ:IMRN - US45254U1016 - ADR
IMRN Key Statistics, Chart & Performance
The current stock price of IMRN is 1.68 USD. In the past month the price decreased by -21.86%. In the past year, price decreased by -10.63%.
IMRN Latest News, Press Relases and Analysis
IMRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About IMRN
Company Profile
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Company Info
IMMURON LTD-SPON ADR
62 Lygon Street, Level 3
Melbourne VICTORIA 3053 AU
CEO: Jerry Kanellos
Employees: 6
Phone: 61398245254
IMMURON LTD-SPON ADR / IMRN FAQ
What does IMRN do?
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Can you provide the latest stock price for IMMURON LTD-SPON ADR?
The current stock price of IMRN is 1.68 USD. The price increased by 3.7% in the last trading session.
What is the dividend status of IMMURON LTD-SPON ADR?
IMRN does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMRN stock?
IMRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is IMRN stock listed?
IMRN stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of IMMURON LTD-SPON ADR (IMRN)?
IMMURON LTD-SPON ADR (IMRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
Can you provide the short interest for IMRN stock?
The outstanding short interest for IMMURON LTD-SPON ADR (IMRN) is 0.28% of its float.
IMRN Technical Analysis
IMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMRN. While IMRN seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMRN Financial Highlights
Over the last trailing twelve months IMRN reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 25.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.49% | ||
| ROE | -64.64% | ||
| Debt/Equity | 0 |